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Importance of NO/EDRF for glomerular and tubular function: Studies
in the isolated perfused rat kidney. The effect of the addition of
No-nitro-L-arginine (L-NNA, 10 and 100 M) to isolated rat kidneys
perfused with a complex medium containing 21 amino acids has been
studied. A cyclooxygenase inhibitor was added throughout to block
prostaglandin synthesis. L-NNA caused significant reductions in renal
perfusion flow rate (PFR, 9.8 l.4vs. 15.9± 1.lml. min' gkidney
wt', P < 0.0001), glomerular filtration rate (GFR, 566 57 vs. 705
47 j.d . min' . g kidney wF', P < 0.05) and an increase in the relative
filtration fraction (%FF, 7.0 0.6 vs. 5.2 0.4%, P < 0.05) compared
to control kidneys. L-NNA perfused kidneys had a lower absolute
sodium (72 9 vs. 88 4 mo1. min' g kidney wt, P <0.05) and
glucose reabsorption (3.5 0.5 vs. 5.4 0.4 mol min g kidney
wF', P < 0.05), corresponding mainly to a lower sodium and glucose
filtration. However, the relative reabsorption of sodium and glucose in
the presence of L-NNA was attenuated, too (82.8 2.0 vs. 87.0 3.3%
P < 0.05and 91.3 1.1 vs. 94.1 0.5%,P <0.05). Potassium handling
and protein excretion were not changed significantly; fractional protein
excretion increased slightly with the addition of L-arginine (47 5 vs.
55 7 ng. sal', P < 0.05). The differences between control and
L-NNA treated kidneys (with the exception of differences in FRGIUC)
could be fully (L-NNA, 10 tM) or partially (L-NNA 100 m) reversed
by adding L-arginine (1 mM) to the perfusion medium. The observed
results could be obtained in two different rat strains (Sprague-Dawley
and Wistar). Only L-NNA and L-arginine caused the observed changes,
while D-NNA and D-arginine were without effect. It is concluded that
NO/EDRF is basally released from the isolated perfused rat kidney, and
is of importance not only in the regulation of renal hemodynamics but
also in the regulation of renal tubular function.
Endothelium-derived relaxing factor (EDRF) has attracted
growing interest over recent years. After Furchgott and Za-
wadzki's original observation in 1980 [1], Palmer, Ferrige and
Moncada showed that nitric oxide (NO) or a closely related NO
containing moiety is the active principle of EDRF [2] and that
this NO probably derives from L-arginine [3]. It was further
found that production of NO from L-arginine can be competi-
tively and selectively inhibited by L-arginine analogues, which
have been changed at the guanidino end of the molecule, like
Nw-methylarginine (L-NMA) and Nw-nitro-L-arginine (L-
NNA) [4, 5]. The inhibitory effect is stereospecific (neither
D-NMA nor D-NNA shows any inhibitory effect).
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It is now known that not only endothelial cells, but a variety
of cells and tissues, such as neutrophils, macrophages and mast
cells [6—8], glomerular endothelial cells [9, 101, kidney epithelial
cells [11], glomerular mesangial cells [12, 13] and even smooth
muscle cells [14] are able to release NO. In addition, smooth
muscle is no longer the only effector organ known. NO/EDRF
can stimulate formation of cGMP, the second messenger, in
platelets [15], mesangial [9, 10] and kidney epithelial cells [11,
16]. In some cell types NO/EDRF has even been shown to
function as an autocrine "hormone", being produced and
reacting on the same cell, for instance mesangial cells [12],
porcine kidney epithelial cells [16] and smooth muscle cells
[171.
It has been shown by us and others that NO/EDRF, released
from the kidney under basal conditions, influences renal vascu-
lar resistance (RVR) in vitro [18—22] and in vivo [23—261. The
effects of NO/EDRF are mediated by the intracellular messen-
ger cyclic GMP, which is released from the kidney under basal
conditions and which responds to stimulation by ACh [22, 27].
However, the EDRF inhibitors used most commonly to
delineate EDRF effects, namely hemoglobin, methylene blue
and gossypol pose problems due to their unspecific effects.
Gossypol is a direct vasorelaxant, methylene blue is able to
release norepinephrine from sympathetic nerves [20, 28] and
hemoglobin can lead to the release of vasoconstrictive pros-
taglandins [29]. The newer, selective NO/EDRF synthase in-
hibitors possess different selectivities, probably due to the
existence of different enzymes responsible for NO/EDRF syn-
thesis. L-NNA has been shown to be selective for brain and
endothelial cell NO-synthase and not for macrophage NO-
synthase [30].
To investigate NO/EDRF mechanisms L-arginine has been
employed to reverse the inhibitory action of L-NNA [4, 5].
Arginine is present in human and rat blood in concentrations
of 200 M [31, 32]. The kidney is the major organ of arginine
production by the synthesis of arginine from intestinal or liver
derived citrulline [33].
However, in vivo L-arginine will also cause an increase in
growth hormone and insulin secretion [34, 35] and insulin again
has been shown to increase GFR and FR Na, possibly via
stimulation of prostaglandin synthesis [36]. The use of the
isolated perfused kidney model allows us to distinguish between
such extrarenal and intrarenal control mechanisms.
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The purpose of the present study was to investigate the effect
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of a specific inhibitor of NO/EDRF (L-NNA) on renal vascular
resistance and tubular function of the isolated perfused rat
kidney in the absence of extrarenal influences. Reversibility
was tested by the addition of L-arginine, the substrate for
NO/EDRF synthesis and sodium nitroprusside (SNP), a sub-
stance which directly releases nitric oxide.
Methods
Male Sprague-Dawley (N = 32) or Wistar (W cryptorchic/
Ztm strain, N = 5) rats with free access to food (Altromin
standard pellets) and tap water up to the time of the experiment
were used. The rats, weighing 250 to 350 g were anaesthetized
with thiopental-sodium (Trapanal® Byk Gulden, Konstanz,
Germany, 100 mg/kg i.p.). The right kidney was perfused as
described by Schurek and Alt at an effective perfusion pressure
of 100 mm Hg monitored through the inner part of a double-
barreled cannula situated in the aorta at the origin of the renal
artery [371. Perfusion pressure was held constant by a feedback-
regulated perfusion pump. The ureter was cannulated with a
short polypropylene catheter (PP-b, 5 mm) connected to a
larger polyethylene catheter (PE-50, 80 mm) to prevent ureteral
back pressure. Perfusion flow rate (PFR) was measured in
addition to the pump derived signal with an electromagnetic
flowmeter (Statham, SP-2202) at the venous outflow site, oxy-
gen partial pressure was measured in an aliquot of the venous
outflow, drawn through a Clark type electrode, and in the
arterial medium channeled via a bypass. The basic perfusion
medium consisted of a modified Krebs-Henseleit solution [37]
(37.5°C) containing 5 g/100 ml of dialyzed bovine serum albumin
(fraction V, Sigma) and (mM): Na 140, K 5, Ca2 2.5, Mg2
1.2, C1 117, HC03 27.5, HPO4 1.0, urea 6, pyruvate 0.3,
lactate 2.1, a-ketoglutaric acid 1.0, malic acid 1.0, creatinine
0.13, glucose 8.3, neomycinsulphate 6500 U/liter; and a mixture
of amino acids (Sigma) devoid of arginine. The composition of
the amino acid mixture is shown in Table 1. The cyclooxygen-
ase inhibitor sodium-diclofenac (10 LM) was added to the
perfusion medium to prevent possible interference from endog-
enously formed vasoactive prostaglandins. We have shown
previously that sodium diclofenac at this concentration sup-
presses renal prostaglandin synthesis by about 90% [20]. Poly-
fructosan (Laevosan, Linz, Austria) (1 g/liter) was added for
determination of the glomerular filtration rate (GFR) [37, 38].
The perfusate (containing albumin) was dialyzed against a
20-fold larger volume of filter sterilized buffer (Ca2" 1.2 mM;
Mg2" 0.6 mat, basic medium), devoid of albumin. Arginine
vasopressin (10 mU/liter) was added to the dialysate at the start
of the experiment in a physiological concentration which is
without vasopressor effects but which allows production of a
concentrated urine. The solution was oxygenated with a pre-
warmed and moistened gas mixture (95% 02/5% C02). The pH
was 7.38 to 7.42 in the prewarmed medium and did not change
after addition of SNP, L-arginine or any of the arginine ana-
logues used.
Experimental protocols
After starting the perfusion, an equilibration period of 30
minutes was allowed before the first urine was sampled. Urine
was sampled in 7.5 minute intervals. Drugs were added to the
dialysate to allow thorough mixing. The compounds used were
all dissolved in buffer. In all experiments 100 jM sodium
Amino acid
Group II perfusion Rat plasma
mM
N-acetyl-tyrosine 0.09 —
L-alanine 1.45 0.46
L-asparagine 0.13 0.05
L-aspartic acid 0.32 0.04
L-cystcine 0.18 o.ola
L-glutamic acid 1.48 0.29
L-glutamine 0.40 0.46
Glycine 1.45 0.39
L-histidine 0.43 0.05
L-isoleucine 0.24 0.07
L-leucine 0.42 0.12
L-lysine 0.55 0.45
L-methionine 0.12 0.03
L-ornithine 0.15 0.06
L-phenylalanine 0,26 0.05
L-proline 0.52 0.22
L-serine 0.21 0.20
L-threonine 0.56 0.25
L-tryptophan 0.07 0.09a
L-tyrosine 0.04 0.08
L-valine 0.30 0.17
0.23
nitroprusside—a drug which acts by spontaneous release of
nitric oxide contained within its molecular structure—was
added at 120 mm and its effect observed for the next 15 mm.
This was done to show that the isolated kidney was still able to
react to nitric oxide at the end of the experimental period.
Experiment I. (Control, N = 10). Perfusion of right kidneys
derived from Sprague-Dawley rats was started with the basic
medium. After 90 minutes L-arginine (1 mM) was added to the
perfusion medium.
Experiment II. (L-NNA). As experiment I; at 60 minutes
L-NNA (10 tM, N = 5; 100 ELM, N = 8) was added to the
perfusate until the end of the experiment.
Experiment III. (Enantiomers, N = 5). These experiments
were performed to exclude unspecific amino acid effects. At 60
minutes D-NNA (100 jsM) was added, at 75 minutes L-NNA
(100 /LM), at 90 minutes D-Arg (1 mM) and at 105 minutes L-Arg
(1 mM).
Experiment IV. (Erythrocytes, N = 4). As experiment 11(100
/LM L-NNA); 5% washed human erythrocytes were added to
the basic perfusion medium at the start of the experiment and
the in line filter excluded (12 M pore size). These experiments
were performed to mimic the in vivo situation more closely and
to observe how the presence of the natural NO-inhibitor hemo-
globin affected the experimental results.
Experiment V. (Wistar rats, N = 5). As experiment 11(100
sM L-NNA) but kidneys were taken from Wistar rats. These
experiments were performed to exclude a purely strain specific
effect.
Analytical methods
Glucose was measured enzymatically by the hexokinase/
glucose-6-phosphate dehydrogenase method (Boehnnger,
Mannheim, Germany), and polyfructosan was measured after
Table 1. Amino acid composition of perfusion medium compared
with physiological composition of rat plasma
L-arginine 1 mai
Unmarked plasma [32] except in a, where [31]
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Fig. 1. A. Effect of Nw-nitro-L-arginine (L-NNA) and L-arginine on the relative change in perfusate flow rate (PFR, 60 mm = 100%). Values are
means SE. At 60 minutes L-NNA (0, 100 M, N = 8 ore, 10 M, N = 5) in buffer or plain buffer solution (A, control, N = 10) was added.
At 90 minutes L-arginine (1 mM) and at 120 minutes sodium mtroprusside (100 M) were added to the buffer solution. *P < 0.05, < 0.001
compared to control kidneys using ANOVA, followed by Fisher's protected least-significant difference test; § P < 0.05, §IP < 0.001 compared
to the last phase before a new drug was added using paired t-test for intra-expenmental comparisons. B. Effect of the D-enantiomers (•, N = 5)
of NNA and arginine on PFR. At 60 minutes D-NNA (100 MM), 75 minutes L-NNA (0, 100 SM), 90 minutes D-Arg (1 mM) at 105 minutes L-Arg
(1 mM) and at 120 minutes SNP (100 .LM) were added to the perfusate. Symbol (A) is control. tP < 0.05 compared to kidneys treated with L-NNA
acid hydrolysis by including a glucose-6-phosphate isomerase
reaction into the assay [38]. The polyfructosan clearance was
used as an estimate of the glomerular filtration rate (GFR).
Sodium and potassium were analyzed by flame photometry
(IL 543 flame photometer, Instrumentation Laboratory, Lex-
ington, Massachusetts, USA).
Albumin was measured using a protein-dye binding method
with Coomassie-blue [39]. Osmolality was analyzed with a
vapor pressure osmometer (5100 B Vapor pressure osmometer,
Wescor Inc, Logan, Utah, USA).
Materials. The suppliers were as follows: sodium-pyruvate
and enzymes for polyfructosan and glucose analysis from
Boehringer Mannheim; urea, glutamic acid, a-ketoglutaric acid,
malic acid and creatinine from Merck, Darmstadt, Germany;
sodium lactate and nitro-D-arginine from Serva, Heidelberg,
Germany; neomycinsulphate from Byk-Gulden, Konstanz,
Germany; L-aminoacids, Nnitro-L-arginine, D-arginine, so-
dium nitroprusside and bovine albumin from Sigma, Munich,
Germany; polyfructosan from Laevosan, Linz, Austria and
arginine-vasopressin from Parke-Davis, Munich, Germany. Di-
clofenac was a gilt from Geigy Pharma, Wehr, Germany.
Calculations and statistical analysis. All results are ex-
pressed for 1 g wet kidney weight, and the left decapsulated
kidney was used as a weight basis for calculation. Control of
unperfused left and unperfused right kidney weights had shown
that kidney weights differ by only 2% (left kidney 1.16 0.04 g
vs. 1.13 0.03 g right kidney, N = 20).
All data are reported as means SE. For statistical compar-
isons data were expressed as percentage of the value reached at
60 minutes. Differences in the response between control and
treated kidneys were tested for statistical significance using
one-way analysis of variance (ANOVA), followed by Fisher's
protected least-significant difference test. The paired t-test was
used to test for intra-experimental changes. Significance was
accepted at the 0.05 level of probability.
Results
Perfusion flow rate
After addition of L-NNA (100 /LM) perfusion flow rate (PFR)
declined rapidly to 60% of control values. L-Arg (1 mM) caused
a significant rise, albeit not to control values. Addition of SNP
increased PFR to control levels. Similar results could be
obtained with a lower concentration of L-NNA (10 M, Fig.
1A). The onset of vasoconstriction, however, was slower and
the recovery after addition of L-Arg (1 mM) was complete. The
maximal response of vasoconstriction after 10 /.LM of L-NNA
was not significantly different from that of 100 M L-NNA.
D-enantiomers (Fig. 1B) of NNA and D-Arg showed no
effect. The absolute values for all parameters are given in
Tables 2 and 3. Kidneys perfused with erythrocytes and kid-
neys from Wistar rats had different basal flow rates, but the
effects of L-NNA and L-Arg were comparable (Table 4). The
onset of vasoconstriction following L-NNA was somewhat
slower in Wistar rats than in Sprague-Dawley rats.
Glomerular filtration rate
The glomerular filtration rate (GFR) declined to about 80% of
control levels at 90 minutes. Again 100 jiM L-NNA reduced
GFR faster than 10 jiM, and again the effect at 90 minutes was
not significantly different between the two study groups. The
effect of 10 jiM L-NNA was completely reversible after addition
U-0
03C
(U
-c
C-)
A B
6060
4040
20 20
.E
0 0 003C(5
—20 C-)
—40
—60
L-N NA
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4 L-Arg
90 105 120 135
—20
-40
—60
Time, minutes
D-Arg I T L-Arg
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Table 2. Functional parameters of isolated perfused rat kidneys perfused with NNA 100 MM and NNA 10 LM and control kidneys
Perfusion time, minutes
L-Arg +SNP
(1mM) (I00MM)
Parameter Experiment 37.5—45 52.5—60 67.5—75 82.5—90 97.5—105 112.5—120 127.5—135
PFR
ml min' g kidney wF'
NNA 100 /SM
NNA 10 MM
Control
17.7 1.7
17.3 1.3
18.0 0.9
17.1 1.6
16.6 1.3
17.2 0.9
11.1 i.5"
13.5 1.3,6
16.6 1.0
9.8 1,4b
11.0 1,4b
15.9 1.1
13.2 13b,d
17.9 2.56
19.0 1•0d
13.1 14b
18.8 2,7
19.7 1.1
21.5 l.3
21.8 3.06
21.6 1,0
GFR NNA 100 /.LM 799 69 776 56 581 57 566 55 639 49b 673 40 932 55"
• min' g kidney wt' NNA 10 MM
Control
752 37
817 52
729 30
758 43
639 46
745 46
582 53
678 46
796 946877 62 752 76826 35 788 336897 566
FF % NNA 100 MM
NNA 10MM
Control
5.1 0.5
4.7 0.4
5.0 0.4
5.4 0.4
5.5 0.6
4.9 0.3
6.6 0.6
6.2 0.7
5.2 0.46
7.0 0.6a
7.7 1.0
5.2 0.4
5.7 0.5
5.9 0.94.7 0.3
5.9 0.4a
4.7 0.8
4.2 0.2
4.5 0.4a
3.7 0.4
4.2 0.3
V NNA 100 LM 112 16 116 18 101 14 130 17 143 236 149 24 272 4C
l.min'.gkidneywF' NNA1OMM
Control
81±27
Ill 21
90±20
112 23
109±18
119 25
116±24
127 25
148±32
175 12
153±31
184 6
192±306
232 116
TNa NNA 100 MM 103 8 101 8 74 8" 69 86 80 86 78 56 97 6
Mmol min' g kidney wt' NNA 10 MM
Control
100 6
101±5
100 4
99±5
90 5
95±5
78 36
83±5
110 56
105±96
100 6
98±6
93 6
99±8
FRNa % NNA 100MM
NNA 10MM
Control
90.7 1.3
93.5 1.9
91.8 1.3
89.9 1.4
92.0 1.7
90.7 2.0
86.5 l.66I
85.7 2.16.6
90.0 2.2
82.9 1.8
82.8 2.08
87.0 3.3
84.1 1.96
84.2 1.3
84.1 2.3
84.6 1.9
82.8 1.5
82.5 1.5
75.3 346
78.1 1.2
77.7 1.7
T01,,c NNA 100 MM 5.0 0.6 4.9 0.5 3.7 0.5ac 3.5 0.5 4.2 o.sa.6 4.4 O.4 5.8 0,56
Mmol . min' g kidney wt' NNA 10 MM
Control
4.8 0.5
5.3 0.4
5.0 0.3
5.3 0.4
4.3 0.486
5.4 0.4
3.6 0.28
5.4 0.4
5.4 0.36
5.7 0.36
4.9 0.3
5.3 0.2
4.7 0.2
5.6 0.3
FRG,,,6 % NNA IOOMM
NNA 10MM
Control
95.6 0.5
95.6 0.3
96.0 0.3
95.1 0.7
95.0 0.6
95.8 0.4
93.5 1.0
93.7 0.4
95.3 0.4
91.2 1.56
91.3 1.18
94.1 0.5
91.9 1.1
91.3 1.0
93.2 1.0
91.1 0.9
89.6 0.9
91.6 1.0
88.0 1.3
87.7 0.8
88.6 1.4
%
Q02
mol . min' . g kidney wt'
NNA 100 MM
NNA 10 MM
Control
NNA 100 MM
NNA 10 MM
Control
84.6 2.6
90.1 2.6
86.9 2.4
4.9 0.3
4.9 0.6
4.9 0.3
83.9 2.7
87.8 3.1
85.8 2.4
4.9 0.3
5.1 0.6
4.9 0.2
80.6 2.88,6
81.0 3.28.6
85.0 2.6
3.8 04b,c
5.1 0.6
4.9 0.2
76.6 2.9a
75,5 5,0"
83.7 2.7
3,7 0,3b
4.1 0.7
4.9 0.2
79.7 2.5k
79.5 36b
79.6 2.5
4,5
5.3 0.86
5.1 0.56
80.7 2.2
76.4 5.18
77.6 1.5
4.5 0.3
5.1 0.7
5.0 0.4
71.1 3.26
70.6 4.8
73.7 2.7
4.6 0.3a
5.0 0.7
4.8 0.4
Protein excretion
Mg. min' . g kidney wt'
NNA 100 MM
NNA 1OMM
Control
28 722 828 4
28 7
24 9
27 4
23 4
28 930 4
25 4
35 11
33 4
33 5'
57 18
45 26
38 4
62 17
47 2
89 3C
75 166
82 12
Prot. excret./GFR
ng. Ml'
NNA 100 MM
NNA 10MM
Control
42 12
28 9
38±5
39 10
32 11
40±5
41 68
43 146
43±7
47 5
54 15
51±9
55 7
66 21
52±6
60 6
81 25
58±4
103 6"99 24
94±19
Values are means SE. At 60 minutes L-NNA (100 MM, N = 8 or 10 MM, N = 5) in buffer or plain buffer solution (control, N = 10) was added.
At 90 minutes L-arginine (1 mM) and at 120 minutes sodium nitroprusside (100 MM) was added to the buffer solution. Abbreviations are: PFR,
perfusate flow rate; GFR, glomerular filtration rate; FF, filtration fraction; V, urine flow rate; TNA, sodium reabsorption; FRN8, fractional
reabsorption of sodium, T01,,6, glucose reabsorption; FR016, fractional reabsorption of glucose, FRH20, fractional reabsorption of water, Q,
oxygen consumption.
a P < b P < 0.001 compared to control kidneys using ANOVA, followed by Fisher's protected least-significant difference test
P < 0.05, "P < 0.001 compared to the last phase before a new drug was added using paired t-test for intra-experimental comparisons
of L-arginine, while the effect of 100 MM was not. D-arginine
and D-NNA (Fig. 2B) were without effect. Erythrocyte per-
fused kidneys and kidneys from Wistar rats had different basal
GFR rates (Table 4), however, the effect of L-NNA (100 MM)
was comparable to that of Sprague-Dawley rats. The reduction
in GFR occurred more slowly in Wistar rats. The addition of
SNP returned all GFR rates to control values.
Filtration fraction
Filtration fraction (FF) increased significantly in L-NNA (100
MM) treated rats. The effect was partly reversible by L-Arg and
completely reversible by SNP. D-enantiomers (Fig. 3B) of
NNA and Arg were without effect. Wistar rats also increased
FF in response to NNA and decreased FF in response to Arg
Erythrocyte perfused kidneys, however, showed the opposite
effect: FF decreased with L-NNA and increased with L-Arg.
SNP returned FF to control values (Table 4).
Urine flow rate
NNA did not significantly change the urine flow rate (V),
L-Arg, D-Arg and SNP increased V. This increase with Arg
could not be observed in Wistar rats.
Sodium and glucose reabsorption
Sodium and glucose reabsorption (TN8 and T016) declined
rapidly to 80% of control values after addition of L-NNA (100
MM); this decline was partially reversed by L-Arg and com-
pletely reversed by SNP. D-NNA (Fig. 4B) and D-Arg showed
no effect compared to the L-enantiomers. Erythrocyte perfused
kidneys and kidneys from Wistar rats both showed a reduction
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Table 3. Functional parameters of isolated perfused rat kidneys perfused with enantiomers of NNA (100 M) and L-Arg (1 mM)
Perfusion time, minutes
D-NNA L-NNA D-Arg L-Arg +SNP
100 M 100 M 1 mM 1 mM 100 tLM
Parameter 37.5—45 52.5—60 67.5—75 82.5—90 97.5—105 112.5—120 127.5—135
PFR 19.1 1.6 19.1 1.9 17.8 1.9 10.0 15b,c 9.0 1,4b,e 13.0 2,0b 24.0 2.2a.C
ml min' . g kidney wt
GFR 844 133 797 179 778 194C 568 220' 532 223a. 588 216' 787 192'
1.il min' g kidney wt
FF % 4.8 0.6 4.9 0.7 5.3 0.8 6.0 1.0 7.6 1.2a.c.e 5.7 0.6" 5.2 1.2
V 109 26 121 36 126 42 122 46 149 55' 130 42 214 60'
1. min' g kidney wt'
TNa 112 16 105 21 101 22 71 25' 62 25 72 26a 93 21'
mol min' g kidney wt'
FRa % 90.6 1.0 89.9 1.3 88.7 l.6e 85.1 2.5 81.4 2.0 84.6 0.9' 82.0 1.4
T01. 5.8 0.8 5.6 1.0 5.4 l.le 3.7 1.la 3.5 l.la 4.0 5.5 1.2"
mo1. min' . g kidney wt'
FR01,, % 95.9 0.4 95.5 0.6 94.7 0.8 91.9 2.0 89.4 2.1 89.6 2.6e 87.6 3.2
FRH2O %
Q02
mol min' g kidney wt'
86.6 1.7
6.2 0.6
85.0 2.3
6.4 0.7
83.9 3.1
6.2 0.6'
78.4 6.0 75.2 5.0
5.3 0.5" 5.1 0,5b.
80.4 2.9
6.2 0.6
76.7 2.6'
6.0 0.5
Protein excretion 39 9 35 9 34 8 27 8 26 T 33 8 133 21'
g min' g kidney wt'
Prot. excret./GFR 47 15 45 13 51 19 63 28 73 27 82 28 246 88
ng.
Values are means SE. N = 5. At 60 minutes D-NNA (100 /.LM), 75 minutes L-NNA (100 tM), 90 minutes D-Arg (1 mM), at 105 minutes L-Arg
(1 mM), and at 120 minutes SNP (100 LM) were added to the perfusate. Abbreviations are: PFR, perfusate flow rate; GFR, glomerular filtration
rate; FF, filtration fraction; V, urine flow rate; TNa, sodium reabsorption; FRNa, fractional reabsorption of sodium; T010, glucose reabsorption;
FR01, fractional reabsorption of glucose; FRH o fractional reabsorption of water, Q02, oxygen consumption.
a p < 0.05, b P < 0.001 compared to control ludneys using ANOVA, followed by Fisher's protected least-significant difference test
'P < 0.05, d p < 0.001 compared to the last phase before a new drug was added using paired t-test for intra-experimental comparisons
P < 0.05 compared to kidneys treated with L-NNA (100 M) only
in TNa and TG,UC with L-NNA (slower in onset in Wistar rats),
and the effect was partially reversible with L-Arg and com-
pletely reversible with SNP (Table 4).
Fractional reabsorption of sodium, glucose and water
Fractional reabsorption of sodium, glucose and water (FRNa,
FRG,UC and FRH20, respectively) declined significantly after
both low and high dose L-NNA. L-Arg reversed the effect of
L-NNA on FRNa and FRH20, and SNP caused an overall fall in
FRNa, FRGIUC and FRH20. D-NNA and D-arginine (Fig, 5B,
Table 3) were without effect. The three parameters decreased in
erythrocyte perfused kidneys and kidneys from Wistar rats
(Table 4), and again the effects on FRNa and FRH20 could be
reversed by L-Arg, and SNP caused a decline in values.
The effects on FRG,UC were generally slower in onset and less
pronounced than the effects on FRNa and FRH2O. L-arginine
increased FRG,UC in Sprague-Dawley rats; however, this in-
crease was only significant in erythrocyte perfused kidneys. In
kidneys from Wistar rats L-arginine caused a further decrease
in FRGIUC.
Oxygen consumption
Oxygen consumption decreased rapidly to 75% of control
values with 100 tM of L-NNA (Table 2). The decline was
slower to occur in 10 /LM L-NNA and it did not reach signifi-
cance. L-Arg partially and SNP completely reversed the 100 LM
L-NNA effect. D-NNA and D-arginine (Table 3) were without
effect and erythrocyte perfused kidneys and kidneys from
Wistar rats behaved similarly to L-NNA 100 iM treated kid-
neys (Table 4).
Protein excretion
Protein excretion did not change significantly with the addi-
tion of L-NNA.
Fractional protein excretion
Fractional protein excretion (that is, protein excretion fac-
tored for GFR) increased slightly with the addition of L-NNA.
L-Arg somewhat and SNP greatly increased protein excretion
and fractional protein excretion (Table 2). D-Arg and D-NNA
showed no significant effects (Table 3). Kidneys from Wistar
rats showed no significant reaction to either L-NNA or L-Arg
when absolute protein excretion was compared; with fractional
protein excretion, however, there was a slight decrease after
addition of L-NNA and a marked increase with the addition of
L-arginine and SNP. Erythrocyte perfused kidneys greatly
decreased protein excretion with NNA and increased it with
L-Arg (Table 4). For fractional protein excretion these effects
were not significant.
Discussion
As is shown here, addition of the NO/EDRF inhibitor
L-NNA causes profound changes in the isolated perfused
kidney of the rat. PFR and GFR decrease, FF increases. Total
and fractional sodium and water reabsorption decline. This can
be partially explained by a reduction in filtered load. However,
since the relative reabsorptions of sodium and water are de-
creased by the NO/EDRF inhibitor L-NNA, the effect of
NO/EDRF is thought to be an increase in the reabsorption of
sodium and water over and above the increase in tubular load.
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Table 4. Functional parameters of isolated perfused rat kidneys
Perfusion time, minutes
L-NNA L-Arg +SNP
IOOILM 1mM 100pM
Parameter 37.545 52.5—60 67.5—75 82.5—90 97.5—105 112.5—120 127.5—135
PFR 9.3 1.2 9.7 1.3 4.5 07 3.9 08" 6.0 09" 6.1 OS' 15.3 1.9c
ml min' g kidney wr' 22.9 0.7 22.9 0.9 15.0 1.2"" 13.1 1.2" 20.5 1.l" 20.7 1.2" 30.2 l.7c
GFR 496 55 548 133 183 63 212 150" 367 iooa 403 70 830 l89
,al. mini g kidney wF'
FF %
1018 37
4.5 0.2
4.5 0.1
1059 51
4.6 0.6
4.6 0.1
927 75 900 74 889 753.1 1.0 2.2 0.1" 4.9 1.3c
5.3 0.4 6.8 0.5a 4.4 O.r
847 69"
5.6 0.5
4.0 0.1
1014 54
5.0 1.1
3.4 0.2
V 6.9 0.5 10.3 3.9 6,1 3,7C 8.9 3.1 19.8 6.5 26.4 9.9 186.4 56.8cpi min' . g kidney wr' 211 5V 271 49R 258 46 264 42 224 28 216 29 412 59C
TNa 72±9 79±20 26±9 23±10" 52±15 57±1o 106±32c
Mmol min' g kidney wC' 131 3 131 6 112 102 7 108 8 102 6 101 7C
FRNa% 99.9 o.oa
90.1 2.2a
99.7 0.1
87.3 2.5a
99.1 0.2c 95.5 3.6 95.5 3.584.9 1.7 80.1 1,la 85.1 2.6a.c 97.1 l.6c85.2 2.9a 86.4 5.869.8 3.0
T01
tcmol . min' g kidney wF'
3,3 0.4
7.0 0.2
3.7 0.9
7.2 0.4
1.2 0.4 1.1 0.5" 2.46.2 0.5 6.0 0.5" 5.8 o.sa 2.7 0.5'5.4 O.'t" 5.3 l.2c6.1 0.3"
FR011 % 96.9 0.2
95.3 0.6
96.7 0.6
95.0 0.4
96.4 1.1 95.8 1.8 94.5 2.3
93.8 0.5 91.1 0.7" 89.8 1.0"
96.0 0.
88.4 1.oa
935 l.8a
83.4 1.sa
FRH20 % 98.6 0.2
83.4 3.0"
98.5 0.3
78.4 2.8
97.9 0.4 92.1 6.2 92.5 6.3
76.2 3.4 72.7 3.1" 77.7 2.2
95.7 3.2
77.2 2.1
86.6 10.4
68.2 2.2
Q02
.tmol min' g kidney wF'
3.3 0.5
6.4 0.3
3.4 0.4
6.4 0.4
2.2 0.4 1.9 0.5" 2.7 0.7""
5.5 5.3 0.2" 6.3 0.4"
2.8 0.6"
6.2 0.5
4.2 0.6""
6.3 0.7"
Protein excretion 4.6 1.5 4.0 0.8 1.6 0.5" 1.9 0.6 6.4 2.2a 7.3 2.4a 65.4 2.15
/Lg.min'.gkidneywt' 84±26 77±23 68±23 54±14 67±19a 68±17a 169±53
Prot.excretjOFR 10±3 9±3 11±3 31±27 28±14 22±9 103±41
ng.d' 82±24 73±23 74±25 63±17" 81±22" 84±20 165±47"
Values are means 5E. At 60 minutes L-NNA (100 ILM) was added to erythrocyte perfused kidneys (N = 4) or to kidneys isolated from Wistar
rats (N = 5). At 90 minutes L-arginine (1 mM) and at 120 minutes sodium nitroprusside (100 jiM) was added to the buffer solution. Abbreviations
are: PFR, perfusate flow rate; GFR, glomerular ifitration rate; FF, filtration fraction; V, urine flow rate; TN, sodium reabsorption; FRN, fractional
reabsorption of sodium; T0111, glucose reabsorption; FR01, fractional reabsorption of glucose; FR,.,20, fractional reabsorption of water; Q02,
oxygen consumption.
a p c 0.05, "P c 0.001 compared to control kidneys using ANOVA, followed by Fisher's protected least-significant difference test
P < 0.05, ' P < 0.001 compared to the last phase before a new drug was added using paired 1-test for intra-experimental comparisons
The effect of L-NNA is dependent on the dose used and can be
partially or completely reversed with L-Arg and SNP. D-NNA
and D-Arg are without effect on the above-mentioned parame-
ters, showing that the observed effects are specifically related to
the precursor (L-arginine) and inhibitor (L-NNA) of NO!
EDRF. The experiments can be reduplicated in a different rat
strain (Wistar), although the effects are somewhat slower in
onset. Addition of erythrocytes to the perfusion medium leads
to the same results, with the exception of FF, which decreases
with L-NNA and increases with L-Arg.
Control kidneys, which are perfused with the basic buffer
medium, devoid of arginine, also show a decline of PFR and
GFR and an increase in FF which is reversible with L-arginine.
Absolute and fractional reabsorption of sodium decline and this
effect, too, is reversible with L-arginine. Thus, arginine deple-
tion itself, without the use of a specific inhibitor of arginine
causes a deterioration in kidney function. We attribute this
effect to inhibition of basal EDRF release from the isolated
kidney, since extrarenal effects of arginine (increase in growth
hormone and insulin secretion [34, 35, 40]) and subsequent
increased prostaglandin synthesis [41] are not possible in an
isolated kidney, and since local prostaglandin synthesis has
been inhibited by cyclooxygenase inhibition.
Studies on the effect of NO/EDRF stimulation or inhibition
on renal hemodynamics have been performed in recent years,
with partially conflicting results. Renal vasodilation [18, 20, 22,
26, 27, 42], a decrease in filtration fraction [25] and an increase
in urinary cGMP excretion [22, 27] have been observed unani-
mously. Walder, Thiemermann and Vane even reported regu-
lation of regional blood flow, namely an increase in cortical
blood flow, in an in vivo rat model [42]. Effects on GFR and on
renal tubular functions are less clear, however. Also, the site of
production and action of NO/EDRE in the kidney remains to be
elucidated.
Tolins et al as well as Gardiner et al in in vivo rat models have
reported no change in GFR with L-NMA as the specific
NO/EDRF inhibitor [22, 23]. Disparate results have been
achieved with addition of arginine as the NO/EDRF precursor,
one group, using a high concentration of arginine (10 mM)
showing a decrease in GFR [431, and another group showing an
increase [44]. Both studies, however, did not make use of a
cyclooxygenase inhibitor to exclude prostaglandin effects. This
seems important since Hirschberg et al [41] have shown that the
arginine induced increase in GFR may be prevented by cyclo-
oxygenase inhibition. Vogel et al [451, using hemoglobin as
NO/EDRF inhibitor also saw a massive decline in GFR, how-
ever, unspecific effects of hemoglobin, again including prosta-
glandin effects, have been described [29].
Baylis, Harton and Engels saw a small but significant de-
crease of GFR with both L-NMA and L-NNA in the conscious,
chronically instrumented Sprague-Dawley rat [251.
The variable effects of NO/EDRF inhibition or stimulation on
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Fig. 2. A. Effect of Nw-nitro-L-arginine (L-NNA) and L-arginine on the relative change in glomerular filtration rate (GFR, 60 mm = 100%).
Values are means SE. At 60 minutes L-NNA (0, 100 tiM, N = 8 or•, 10 M, N = 5) in buffer or plain buffer solution (A, control, N = 10)was
added. At 90 minutes L-arginine (1 mM) and at 120 minutes sodium nitroprusside (100 .tM) were added to the buffer solution. *p < 0.05, <
0.001 compared to control kidneys using ANOVA, followed by Fisher's protected least-significant difference test; §P < 0.05, §P < 0.001
compared to the last phase before a new drug was added using paired t-test for intra-experimental comparisons. B. Effect of the D-enantiomers(•, N = 5) of NNA and arginine on GFR. At 60 minutes D-NNA (100 .tM), 75 minutes L-NNA (0, 100 MM), 90 minutes D-Arg (1 mM) at 105 mm
L-Arg (1 mM) and at 120 minutes SNP (100 M) were added to the perfusate. tP < 0.05 compared to kidneys treated with L-NNA (100 M) only.
GFR observed in the studies mentioned above may have
several reasons. Firstly in vivo effects of NO/EDRF stimulation
or inhibition may differ from effects seen in the isolated per-
fused kidney due to the complexity of an in vivo model. ACh,
for instance, not only causes NO/EDRF but also prostaglandin
release [20], and prostaglandins have been shown to be impor-
tant modulators of GFR in states of decreased renal perfusion
[461. Prostaglandins as well as NO/EDRF may lead to an
increase in RPF and urine volume as shown by Salom et a! in an
in vivo dog model [47]; ii one system is inhibited by either using
a NO/EDRF or a cyclooxygenase inhibitor, the other appears to
fully compensate for it [47]. We therefore believe that prosta-
glandin synthesis inhibition is mandatory to observe direct renal
effects of NO/EDRF. L-NMA furthermore not only leads to an
increase in renal vascular resistance in vivo, but also to an
increase in total peripheral resistance, which makes the inter-
pretation of isolated effects on the renal vasculature difficult
[48, 49]. Welch et a! saw a decrease in GFR with L-NMA in an
in vivo model only when the renal perfusion pressure was
maintained at control levels by means of an aortic snare [50].
An increase in total peripheral resistance may lead to counter-
regulatory mechanisms, one of which could be an increase in
atrial natriuretic peptide due to atrial stretch leading to natri-
uresis, smooth muscle relaxation and an increase in cyclic
GMP. In vivo models therefore are well suited to show overall
effects of NO/EDRF inhibition but make the interpretation of
direct NO/EDRF effects in specific organs difficult.
Another reason for a lack of effect on GFR may lie in the
choice of the specific NO/EDRF inhibitor. Most studies per-
formed up to now made use of L-NMA, which was the first
specific inhibitor of NO/EDRF [4]. Recent findings, however,
show that the choice of L-NMA may be questionable. The
arginine analogues which have been introduced as NO/EDRF
inhibitors possess different potencies in different cell and organ
systems [30] probably due to the existence of more than one
enzyme which can cleave nitric oxide from l-arginine (NO-
synthase). L-NNA has been shown to be a more potent
inhibitor of brain and endothelial cell NO-synthase (IC50 = 0.05
M) than L-NMA (IC50 = 10 tM) [30]. Fasehun et al [51]
observed that L-NNA was more potent than L-NMA in inhib-
iting endothelial cell NO-synthase, and Walder et a! could show
that L-NMA was less effective than L-NNA in reducing renal
cortical blood flow [42]. One further disadvantage of L-NMA
may be that it can be metabolized to citrulline and subsequently
to arginine as shown by Hecker et al [52]. These findings and
preliminary experiments using both inhibitors and investigating
their effect on renal blood flow prompted us to choose L-NNA
as the specific NO/EDRF inhibitor. In our experiments we also
depleted kidneys of L-arginine by omitting L-arginine from the
perfusion medium which may have enhanced the effect of
L-NNA. Our findings show that NO/EDRF does maintain GFR
under conditions of constant renal perfusion pressure.
Whether the reduction in GFR caused by NO/EDRF inhibi-
tors, which is less marked than the reduction in RPF, is solely
due to a reduced RPF rate and an insufficient increase in FF is
not clear. Another appealing theory is the involvement of
mesangial cells in the NO/EDRF response of GFR. Kon, Harris
and Ichikawa [21] have shown that the glomerular capillary
ultrafiltration coefficient (Kf) is reduced with NO/EDRF inhibi-
tion together with a vasoconstriction of the efferent arteriole.
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Fig. 3. A. Effect of Nw-nitro-L-arginine (L-NNA) and L-arginine on the relative change in filtration fraction (FE, 60 mm = 100%). Values are
means SE. At 60 minutes L-NNA (0, 100 /LM, N = 8) in buffer or plain buffer solution (A control, N 10) was added. At 90 minutes L-arginine
(1 mM) and at 120 minutes sodium nitroprusside (100 MM) were added to the buffer solution. *J? < 0.05, < 0.001 compared to control kidneys
using ANOVA, followed by Fisher's protected least-significant difference test; §P < 0.05, HP c 0.001 compared to the last phase before a new
drug was added using paired t-test for intra-experimental comparisons. Symbol (E) is erythrocytes. B. Effect of the 0-enantiomers (•, N = 5) of
NNA and arginine on FF. At 60 minutes D-NNA (100 /.tM), 75 minutes L-NNA (100 MM), 90 minutes D-Arg (I mM) at 105 minutes L-Arg (1 mM)
and at 120 minutes SNP (100 MM) were added to the perfusate. tP < 0.05 compared to kidneys treated with L-NNA (100 jiM) only.
Glomerular mesangial cells due to their contractile properties
play a central role in the regulation of K. These cells have been
shown to respond to NO/EDRF with an inhibition of the
angiotensin II induced reduction in a cross sectional area [101
and an increase in cGMP production [91.
Also, the small increase in fractional albumin excretion
observed after addition of arginine in our model could be due to
an increase in filtration surface area due to mesangial cell
relaxation. The finding that arginine causes an increase in
albumin excretion is not new, however. It has been shown to
occur in rats in vivo [431 and in humans [531. Mogensen [53]
ascribed the increase in albumin excretion in humans to an
inhibition of tubular protein reabsorption by arginine.
The intrarenal site of NO/EDRF synthesis and of NO/EDRF
effects is not known precisely. Ito, Johnson and Carretero [54]
showed that L-NNA decreased the basal diameter of rabbit
afferent arterioles by about 20%. Data on an effect Qf a specific
NO/EDRF inhibitor on isolated efferent arterioles are not
available to our knowledge. Loutzenhiser, Hayashi and Epstein
[55] reported that addition of hemoglobin inhibited ACh in-
duced relaxation of the efferent arteriole in the isolated perfused
rat kidney, and interpreted this as evidence for the existence of
two EDRFs. However, another possible interpretation is that
nitric oxide is produced in the region of the afferent arteriole or
within the glomerulum, only, and hemoglobin scavenges this
NO as NO-heme [56] still allowing the autocrine action of
NO/EDRF but inhibiting the luminal transport of NO to the
efferent arteriole. This would also explain the finding of a lack
of increase in FF with NO/EDRF inhibition in erythrocyte
perfused kidneys, since no effects of NO/EDRF inhibition or
stimulation would be expected to occur in the efferent arteriole.
Since FF was even reduced an effect of NO/EDRF inhibition to
reduce the glomerular capillary ultrafiltration coefficient (Kr)
seems likely. We therefore think that NO/EDRF inhibition (no
hemoglobin added) causes constriction in both the afferent and
efferent arteriole via inhibition of NO production in the afferent
arteriole and/or glomeruli. If the constriction was preglomerular
only, the fall in PFR should be accompanied by a fall in GFR of
comparable magnitude, which is not the case in our model. If
the constriction were postglomerular only there should be no
decline in GFR at all.
The finding that NO/EDRF inhibition caused a reduction in
FRNU and that this effect was reversed by L-arginine was
unexpected. Experiments using SNP, a substance directly
releasing nitric oxide, ACh, an endothelium dependent vasore-
laxant, cGMP (the second messenger of NO/EDRF) or
8-bromo-cyclic GMP, a stable form of cGMP, had always
shown a decrease rather than an increase in FRNa [47, 57, 58].
It has been shown, however, by Mohrmann, Cantiello and
Ausiello [58] that SNP is able to completely block the amiloride-
sensitive Na uptake in a renal epithelial cell line, a pathway
used by ANP. Thus the effect of SNP on sodium excretion does
not necessarily mimic the effect of NO/EDRF formed by
NO-synthase. Another reason for the observed decrease in
FRNa with SNP may be the large increase in GFR which
increases the tubular solute load over the resorptive capacity of
the isolated kidney preparation.
Salom, Lahera and Romero [471 have shown that the ACh
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Fig. 4. A. Effect of Nw-nitro-L-arginine (L-NNA) and L-arginine on the relative change in absolute sodiu,n reabsorption (TN, 60mm = 100%).
Values are means SE. At 60 minutes L-NNA (0, 100 /LM, N = 8 ore, 10 LM, N = 5) in buffer or plain buffer solution (control, N = 10) was
added. At 90 minutes L-arginine (1 mM) and at 120 minutes sodium nitroprusside (100 /LM) were added to the buffer solution. < 0.05, <
0.001 compared to control kidneys using ANOVA, followed by Fisher's protected least-significant difference test; §P < 0.05, §IP < 0.001
compared to the last phase before a new drug was added using paired t-test for intra-experimental comparisons. B. Effect of the D-enantiomers(•, N = 5) of NNA and arginine on TN. At 60 minutes D-NNA (100 jsM), 75 minutes L-NNA (100 sM), 90 minutes D-Arg (1 mM) at 105 minutes
L-Arg (1 mM) and at 120 minutes SNP (100 M) were added to the perfusate. tP < 0.05 compared to kidneys treated with L-NNA (100 iLM) only.
induced natriuresis could neither be blocked by cyclooxygenase
nor by NO-synthase inhibition, making a prostaglandin or
NO/EDRF related effect on natriuresis unlikely. Lahera et a!
investigated the effect of ACh in an in vivo dog model and found
an increase in renal blood flow, diuresis and natriuresis; Nw-
monomethyl-L-arginine (L-NMA), another inhibitor of EDRF,
had no effect on its own, but inhibited the ACh-induced
increase in renal blood flow, leaving the natriuresis unchanged
[26]. The natriuretic effect observed with direct cGMP applica-
tion is probably due to the fact that cGMP is also the second
messenger of ANP [581.
Baylis et al [25] in an in vivo rat model observed a significant
reduction in FRNa after inhibition of basally produced NO!
EDRF with L-NMA and L-NNA. Neuringer et a! [59] also
reported a significant reduction in FRNa in normal and DOCA-
salt hypertensive rats after infusion of L-NAME; furthermore,
a reduction in transport-dependent oxygen consumption could
be observed in suspensions of inner medullary collecting duct
cells. Recently Green, Ruiz and Arruda [60] have shown that
8-bromo-cyclic GMP can also stimulate the Na-H antiporter
in renal brush border membranes and thus increase sodium
uptake. It has been shown that porcine renal epithelial cells
possess NO-synthase and are able to form cGMP [10, 11]. We
therefore believe that the reduction in FRNa after NOIEDRF
inhibition observed by us is, at least partially, due to a specific
tubular effect of NO/EDRF. Pressure natriuresis may also have
played a role in the decrease of FRNa since we did not control
interstitial pressure after application of L-NNA. Unspecific
effects like a reduction in partial oxygen pressure in the renal
tubules due to the reduction in RPF also cannot be excluded,
however, in our model a lowering of RPF or GFR correlated
with a higher rather than lower reabsorption of sodium.
In conclusion, NO/EDRF derived from L-arginine not only
influences renal hemodynamic parameters (PFR, GFR, FF) but
may also affect tubular functions (sodium and water reabsorp-
tion), and possibly also albumin excretion.
Reprint requests to Dr. JOrg Radermacher, Department of Clinical
Pharmacology, Hannover Medical School, P.O. Box 61 01 80, D-3000
Hannover 61, Germany.
Appendix. Abbreviations
One-way analysis of variance
Nitro-D-arginine
Endothelium-derived relaxing factor
Filtration fraction (%) (100 . GFR!PFR)
Fractional reabsorption of glucose
Fractional reabsorption of water [100— (100. V/
GFR)]
Fractional reabsorption of sodium
Ultrafiltration coefficient
Nw-monomethyl-L-arginine
Nw-nitro-L-arginine
Nw-nitro-L-arginine methyl ester
Nitric oxide
Perfusion flow rate
Oxygen consumption
Renal vascular resistance
Sodium nitroprusside
Glucose reabsorption
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Fig. 5. A. Effect of Nw-nitro-L-arginine (L-NNA)andL-arginine on the relative change in fractional sodium reabsorption (FRNa, 60 mm 100%).
Values are means SE. At 60 minutes L-NNA (0, 100 JLM, N = 8 orU, 10 LM, N = 5) in buffer or plain buffer solution (A, control, N = 10) was
added. At 90 minutes L-arginine (1 mM) and at 120 minutes sodium nitroprusside (100 MM) were added to the buffer solution. J3 < 0.05,
0.001 compared to control kidneys using ANOVA, followed by Fisher's protected least-significant difference test; §P C 0.05, §P C 0.001
compared to the last phase before a new drug was added using paired i-test for intra-experimental comparisons. B. Effect of the D-enantiomers(•, N = 5) of NNA and arginine on FRNa. At 60 minutes D-NNA (100 MM), 75 minutes L-NNA (100 JiM), 90 minutes D-Arg (1 mM) at 105 minutes
L-Arg (1 mM) and at 120 minutes SNP (100 JiM) were added to the perfusate. tP C 0.05 compared to kidneys treated with L-NNA (100 JiM) only.
TNa Sodium reabsorption
V Urine flow rate
(U/P)K/(U/P)1 (urine potassium/plasma potassium)/(urine in-
ulin/plasma inulin)
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